All Posts:non-small cell lung cancer

• Georgetown Investigator Presents Final PAPILLON Trial Results Showing Long-Term Survival in a Subset of Lung Cancer

  Final results from the landmark PAPILLON trial, which changed the standard of care for a difficult-to-treat rare form of lung cancer, confirm that amivantamab, when added to chemotherapy, provides durable clinical benefit and the longest median overall survival reported to date for people with the disease.

  Category: News Release Tags: cancer, clinical trials, lung cancer, non-small cell lung cancer

• FDA Approves Lung Cancer Drug Supported by Georgetown Lombardi Research

  (September 14, 2020) — Julie Shanholtz was having an uneventful summer in 2017 working full time with the same employer she’d had for the past 30 years when she developed an “odd cough” that quickly became severe, but no other symptoms. “I had always been very active and healthy — and didn’t smoke,” the 54-year-old […]

  Category: Lombardi Stories Tags: cancer, cancer research, clinical trials, lung cancer, non-small cell lung cancer